These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 19286392)
21. Infliximab for the treatment of ulcerative colitis. Eshuis EJ; Bemelman WA; Stokkers PC Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804 [TBL] [Abstract][Full Text] [Related]
22. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related]
23. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667 [TBL] [Abstract][Full Text] [Related]
24. In-situ endothelial cell adhesion molecule expression in ulcerative colitis. E-selectin in-situ expression correlates with clinical, endoscopic and histological activity and outcome. Cellier C; Patey N; Fromont-Hankard G; Cervoni JP; Leborgne M; Chaussade S; Barbier JP; Brousse N Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1197-203. PubMed ID: 9471026 [TBL] [Abstract][Full Text] [Related]
25. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Arijs I; Li K; Toedter G; Quintens R; Van Lommel L; Van Steen K; Leemans P; De Hertogh G; Lemaire K; Ferrante M; Schnitzler F; Thorrez L; Ma K; Song XY; Marano C; Van Assche G; Vermeire S; Geboes K; Schuit F; Baribaud F; Rutgeerts P Gut; 2009 Dec; 58(12):1612-9. PubMed ID: 19700435 [TBL] [Abstract][Full Text] [Related]
26. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316 [TBL] [Abstract][Full Text] [Related]
27. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Cucchiara S; Romeo E; Viola F; Cottone M; Fontana M; Lombardi G; Rutigliano V; de'Angelis GL; Federici T Dig Liver Dis; 2008 Jul; 40 Suppl 2():S260-4. PubMed ID: 18598998 [TBL] [Abstract][Full Text] [Related]
28. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Tsukada Y; Nakamura T; Iimura M; Iizuka BE; Hayashi N Am J Gastroenterol; 2002 Nov; 97(11):2820-8. PubMed ID: 12425554 [TBL] [Abstract][Full Text] [Related]
29. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Tsai HH; Punekar YS; Morris J; Fortun P Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845 [TBL] [Abstract][Full Text] [Related]
30. Histological healing after infliximab induction therapy in children with ulcerative colitis. Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025 [TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population. Juliao F; Marquez J; Aristizabal N; Yepes C; Zuleta J; Gisbert JP Digestion; 2013; 88(4):222-8. PubMed ID: 24281150 [TBL] [Abstract][Full Text] [Related]
32. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220 [TBL] [Abstract][Full Text] [Related]
33. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Hibi T; Sameshima Y; Sekiguchi Y; Hisatome Y; Maruyama F; Moriwaki K; Shima C; Saniabadi AR; Matsumoto T Dig Liver Dis; 2009 Aug; 41(8):570-7. PubMed ID: 19211314 [TBL] [Abstract][Full Text] [Related]
34. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735 [TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ; J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336 [TBL] [Abstract][Full Text] [Related]